Open AccessEffect of Sodium Valproate Treatment on the Cardiac Index in New Cases with Status Epilepticus
Author(s) -
Mohammad Radgoudarzi,
Mohammad Vafaee-Shahi,
Fatemeh Naderi
Publication year - 2021
Publication title -
the open neurology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.329
H-Index - 16
ISSN - 1874-205X
DOI - 10.2174/1874205x02115010059
Subject(s) - medicine , status epilepticus , ejection fraction , blood pressure , anesthesia , cardiology , cardiac index , cardiac function curve , epilepsy , adverse effect , heart rate , heart failure , psychiatry
Background: Sodium valproate is an antiepileptic drug primarily used to treat status epilepticus [SE]; however, its effect on cardiac function is unclear. This study aimed to examine the effect of 6 months of sodium valproate treatment on the cardiac index in new cases with status epilepticus. Methods: In this cross-sectional study, 30 cases with status epilepticus [18 boys and 12 girls] who were admitted to the Pediatric Intensive Care Unit of Hazrat-e Rasool Hospital were enrolled. Information on basic demographic and clinical data of all children, such as age, weight, gender, blood pressures, and underlying diseases, was recorded. Echocardiography and electrocardiogram [ECG] were performed for all cases before and after the treatment. Results: There were no abnormalities in ECG parameters [including PR, QRS, and QT intervals] after 6 months of treatment with sodium valproate. No significant differences were found in echocardiographic parameters, including blood pressure, pulmonary artery pressure [PAP], right ventricular [RV] size, diastolic dysfunction,], Tie index, end-diastolic volume [EDV], ejection fraction [EF], and TAPSE before and after study [p>0.05]. Conclusion: Administration of sodium valproate over 6 months is not associated with a serious adverse effect on heart function in children with status epilepticus.